Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29256269 | 1.00 | CA2 (0.38) | CA2MEN1KMT2A | |
| SCHEMBL1758519 | 0.97 | — | — | |
| SCHEMBL2780260 | 0.86 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2387118 | 0.82 | — | — | |
| SCHEMBL29256263 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2A | |
| SCHEMBL785513 | 0.79 | CA2 (0.38) | CA2 | |
| SCHEMBL7291462 | 0.79 | CA2 (0.38) | CA2 | |
| SCHEMBL2385202 | 0.79 | — | — | |
| SCHEMBL20513010 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2A | |
| SCHEMBL23647292 | 0.76 | CA2 (0.44) | CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291191-A1 | TUNABLE SUSTAINED RELEASE OF A SPARINGLY SOLUBLE HYDROPHOBIC THERAPEUTIC AGENT FROM A HYDROGEL MATRIX | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-18 | — | — | US | claimed |
| US-20100285113-A1 | ENHANCED STABILITY OF INVERSE THERMAL GELLING COMPOSITE HYDROGELS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-11 | — | — | US | claimed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| WO-1998040078-A1 | THERAPEUTIC AUGMENTATION OF OXYALKYLENE DIESTERS AND BUTYRIC ACID DERIVATIVES | BEACON LABORATORIES, INC. (US) | 1998-09-17 | — | — | WO | claimed |
| EP-0703921-A1 | GRAFTED CROSS-LINKED POLYOLEFIN SUBSTRATES FOR PEPTIDE SYNTHESIS AND ASSAYS | FORSKNINGSCENTER RISO (DK) | 1996-04-03 | — | — | EP | claimed |
| WO-1995000533-A1 | GRAFTED CROSS-LINKED POLYOLEFIN SUBSTRATES FOR PEPTIDE SYNTHESIS AND ASSAYS | Forskningscenter Risø (DK) | 1995-01-05 | — | — | WO | claimed |
| EP-0344990-B1 | Mitomycin derivatives and intermediates therefor | KYOWA HAKKO KOGYO KK (JP) | 1993-12-15 | — | — | EP | claimed |
| EP-0344990-A1 | Mitomycin derivatives and intermediates therefor | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1989-12-06 | — | — | EP | claimed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | claimed |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | GLAS USA LLC | 2023-10-05 | — | — | US | disclosed |
| EP-4232146-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | Biora Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | CA2 960/4885MEN1 1118/4885KMT2A 4224/4885 |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | TNF, TNFRSF1A, FABP2 | CA2 3630/4885MEN1 1615/4885KMT2A 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.